Background-Despite improvements in the care of patients who have received cardiac transplants, coronary allograft vasculopathy (CAV) remains the most prevalent cause of late allograft failure and cardiac mortality. Few proven therapies are available for this important disease. The presence of coronary collaterals imparts a favorable prognosis in patients with native ischemic heart disease; however, the impact of collaterals in CAV is unknown. Methods and Results-To determine whether the development of coronary collaterals is associated with improved outcomes in patients with CAV, we performed a retrospective analysis of patients followed in the heart transplant program at Barnes Jewish Hospital from 1994 to 2008. The primary end points included all cause mortality and the composite of all cause mortality, retransplantation, and inotrope dependence. We screened 485 patients and identified 59 (12%) subjects with moderate-to-severe CAV. Angiographically visible coronary collaterals were present in 34 (57%) subjects. Kaplan-Meier and Cox multivariable analyses revealed that patients with collaterals had reduced incidence of all cause mortality (hazard ratio, 0.20; P<0.001) and the composite end point (hazard ratio, 0.17; P<0.001). In addition, patients with collaterals had less severe heart failure symptoms as measured by New York Heart Association class. Immunostaining of biopsy specimens revealed that among patients with CAV, the presence of coronary collaterals correlated with increased microvascular density, reduced fibrosis, and decreased left ventricular end-diastolic pressure. Conclusions-Together, these data demonstrate that the presence of coronary collaterals predicts a favorable prognosis in patients with CAV and suggests that interventions aimed at promoting collateral and microvascular growth may serve as effective therapies for this disease. (Circ Heart Fail. 2013;6:773-784.)
R ecent advances in immunosuppression have significantly decreased the incidence of death and allograft failure early after transplantation. 1 However, the prevalence of late allograft failure and associated mortality has remained unchanged during the past 10 years. 1 The major causes of late allograft failure include coronary allograft vasculopathy (CAV), malignancies, and nonspecific graft failure. [2] [3] [4] As the opportunities for retransplantation continue to decline, the development of novel therapies aimed at preserving allograft function has become an important and unmet clinical need.
Among the causes of late allograft failure, CAV continues to be a challenge from both the diagnostic and treatment perspectives. CAV is typically diagnosed either on routine screening angiograms or in the setting of heart failure. Coronary angiography is the gold standard for diagnosis where characteristic pruning of the distal coronary arteries is the predominate feature. Additionally, lesions in more proximal coronary arteries may be present. [5] [6] [7] Intravascular ultrasound has increasingly been used for earlier diagnosis and monitoring of disease progression. [8] [9] [10] Unlike traditional coronary artery disease (CAD), CAV tends to diffusely affect the distal coronary vasculature. 6 
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To date, there are few effective treatments available for patients with CAV. Of these, statin therapy seems to be the most efficacious and seems to reduce disease progression and mortality in randomized studies. 11, 12 Other prospective trials have demonstrated smaller improvement in outcomes for patients treated with sirolimus, everolimus, mycophenolate mofetil, ganciclovir, calcium channel blockers, and angiotensin-converting enzyme inhibitors. [13] [14] [15] [16] [17] [18] Coronary revascularization is limited to percutaneous intervention and serves as a palliative treatment modality in these patients. [19] [20] [21] Despite use of these therapies, CAV remains an important cause of allograft failure and the only definitive therapy is retransplantation.
Previous studies have demonstrated that the development of coronary collateral blood vessels portends a favorable prognosis in patients with CAD and ischemic cardiomyopathy. [22] [23] [24] [25] [26] The prognostic impact of coronary collateral development has not yet been studied in patients with CAV. We hypothesized that the development of coronary collateral vasculature is similarly associated with favorable outcomes in patients with CAV.
To test this hypothesis, we performed a retrospective cohort analysis of all patients who were cared for in the heart transplant program at Barnes Jewish Hospital between 1994 and 2008. Here, we show that patients with CAV who develop coronary collateral vasculature have significantly improved outcomes compared with those without collaterals. In addition, we reveal that patients with CAV who develop collaterals have increased microvascular density, reduced myocardial fibrosis, and decreased left ventricular end-diastolic pressure (LVEDP).
Methods

Study Design
To identify patients with significant CAV, we performed a retrospective analysis of all patients who either received a cardiac transplant at Barnes Jewish Hospital between 1994 and 2008 or received a heart transplant elsewhere and were followed up in our post-transplant program between 1994 and 2008. Patients with significant CAV included those with moderate-to-severe transplant vasculopathy as defined by the International Society for Heart and Lung Transplantation. 27 This distinction was made to exclude patients with mild or trivial disease. Before study initiation, institutional review board (Washington University School of Medicine) approval was obtained and the study conducted in accordance with the approved protocol. The electronic medical record was queried to identify patients with moderate or severe CAV. Available angiograms were reviewed by committee to confirm the presence of moderate or severe CAV as defined by the International Society for Heart and Lung Transplantation.
Patients were then divided into 2 groups: (1) patients with coronary collaterals and (2) patients without coronary collaterals. The presence of coronary collaterals was determined by reviewing the coronary angiogram obtained at the time of CAV diagnosis. Angiograms were reviewed by committee and patients were allocated into the above groups.
Patients were included in the study if they had moderate or severe CAV, 3 years of clinical follow-up (unless a clinical end point was reached), and available coronary angiograms. Exclusion criteria included inadequate follow-up, angiographic, or clinical data. Standard demographic information was obtained from the medical record, including age, sex, reason for transplantation, cardiovascular comorbidities, transplant and heart failure medicines, rejection episodes, cytomegalovirus status, blood type, echocardiographic data, stress testing, LVEDP, heart rate, and blood pressure, as derived from diagnostic catheterization data. Data describing donor characteristics and human leukocyte antigen matching were not available for all patients included in this study and unable to be rigorously examined.
End Points
We used 2 primary end points: all cause mortality and the composite of all cause mortality, chronic inotrope therapy, and need for retransplantation. Each of these end points was prespecified in the study protocol. Mortality events were identified through clinical data and confirmed using the Social Security death index. Chronic inotrope therapy and retransplantation were defined using available clinical data.
Secondary end points included 2 independent measures of heart failure severity. New York Heart Association (NYHA) class, as documented in the clinical record at the time of CAV diagnosis, served as a surrogate for functional class and exertional capacity. LVEDP, recorded at the time of coronary angiography and CAV diagnosis, was used as an objective assessment of allograft dysfunction. Each of these secondary end points was prespecified in the study protocol.
Statistical Analysis
Data were analyzed using SAS version 9.3 (SAS Institute, Inc, Cary, NC). Fisher exact test was used to identify differences in demographic categorical variables between patients with and without collaterals. Wilcoxon-Mann-Whitney tests were used for continuous variables. Kaplan-Meier curves were generated for all cause mortality and the composite outcome. Transplantation date was considered to be time zero. Patient groups (with and without collaterals) were compared via the log-rank test. The Cochran-Armitage trend test was used to examine the percentage of collaterals by NYHA class.
Cox proportional hazards multivariable models were created for each of the coprimary outcomes to adjust for covariates and potential confounding variables. Schoenfeld residuals were used to check the proportionality assumption for all independent variables. The hazard ratio and 95% confidence intervals were reported from these models. The interaction between time from transplant to diagnosis and time to endpoint was included to adjust for nonproportionality.
Student t test and ANOVA were used to compare antibody immunostaining results between different patient groups. The coefficient of determination (r 2 ) was used to describe the relationship among LVEDP, stained picrosirius red area, and stained blood vessel area.
The P values reported in linear regression analyses refer to testing for overall model fit (F test).
Biopsy Specimens
Myocardial biopsy specimens that were previously collected for routine clinical care were obtained from the Department of Pathology. Collected tissues were previously fixed in 10% formalin and stored in paraffin blocks. For patients with CAV, specimens were collected within 1 to 2 months of diagnosis and demonstrated minimal acute cellular rejection (grade O or 1A rejection). A control group was created by randomly selecting posttransplant patients without CAV matched only by year of cardiac transplantation. For each patient, the most recent biopsy specimen was obtained. Patients were excluded if they experienced recurrent rejection, defined as no >2 episodes of 2R or 3R rejection, and defined as no episodes of antibody mediated rejection. Demographic and outcome data were collected for the control group and compared with patients with CAV (Table I in the online-only Data Supplement).
Histology and Immunohistochemistry
Myocardial biopsy specimens were cut into 4 µm sections using standard techniques and mounted on glass slides. Each paraffin block typically contained 3 to 4 myocardial specimens. Immunohistochemistry was performed using the following antibodies: CD31 (1A10), CD34 (QBEnd/10), and smooth muscle actin (SMA; 1A4). The primary antibody was detected using horseradish peroxide-conjugated secondary antibodies and DAB (3,3'-diaminobenzidine) substrate. SMA-immunostained sections were counterstained with hematoxylin. Picrosirius red staining was performed using standard techniques. These assays were performed by the Anatomic and Molecular Pathology core as a component of the Institute of Clinical and Translational Science at Washington University School of Medicine.
To identify the microvasculature, our initial experiments used CD31 (platelet endothelial cell adhesion molecule) and CD34 antibodies, as well as UEA (Ulex europaeus agglutinin) I Lectin. Each of these reagents specifically labeled endothelial cells; however, CD34 immunostaining seemed to give the most consistent and robust signal particularly in older specimens. For this reason, we performed the majority of the analyses using the CD34 antibody. CD31 immunostaining and UEA1 Lectin staining demonstrated consistent findings (data not shown). SMA immunostaining was used to identify arterioles.
For each antibody, 2 to 3 sections were stained. Positive staining was quantified with an automated software package as the percentage area stained. Manual quantification of microvascular density demonstrated a robust correlation with the automated method (data not shown). The following protocol was used. For each myocardial specimen, 2 independent fields from each of the stained sections were photographed at a ×20 magnification. Image J software was used to quantify the percentage area stained. The resulting measurements (typically 6-8) were then averaged to produce a single value to be used in the final analysis. Pircosirius red staining was quantified using an identical method. SMA immunostaining was quantified by manually counting the number of SMA-containing blood vessels per ×20 field. All specimens were stained, photographed, and quantified in blinded fashion.
Results
Study Design and Baseline Characteristics
In total, we identified 485 patients who were transplanted between 1994 and 2008, cared for in our post-transplant program, and had ≥3 years of clinical follow-up. A chart review identified 63 patients who had moderate or severe CAV. Angiographic data were available for 59 of these patients. Coronary angiograms obtained at the time of CAV diagnosis were then reviewed by committee to verify the presence of moderate or severe CAV. Of the 59 angiograms available for review, all were determined to meet criteria for moderate or severe CAV. Examination of baseline demographics demonstrated no significant differences between CAV patients with and without collaterals for several known risk factors, including age, race, diabetes mellitus, cytomegalovirus status, rejection events, heart failure, and immunosuppressive medications. However, there was a significant difference seen between these 2 groups with respect to timing of diagnosis of CAV (Table 1) . Patients with CAV but without coronary collateral blood vessels were diagnosed considerably earlier than those with collateral vasculature, 4.8 versus 7.9 years, respectively (P<0.001). In addition, patients without collaterals had increased heart rate, increased diastolic blood pressure, and reduced pulse pressure compared with patients without collaterals.
Improved Outcomes in CAV Patients With Coronary Collateral Vasculature
To determine whether development of coronary collateral blood vessels is associated with improved outcomes in patients with CAV, we performed a time-to-event analysis using 2 prespecified primary outcomes: all cause mortality and the composite of all cause mortality, retransplantation, and chronic inotrope use. For these analyses, the time of transplantation was considered to be time zero. Kaplan-Meier analysis revealed significantly reduced rates of both the all cause mortality and the composite end point in patients who develop coronary collaterals (both P<0.001; Figure 2 ). The composite end point was primarily driven by all cause mortality. Death occurred in 10 patients (29%) in the collateral group and 20 patients (80%) in the no collateral group (P<0.001). With respect to retransplantation, 1 patient (2.9%) underwent a second transplant in the collateral group, whereas 2 patients (8.0%) required a second transplant in the no collateral group. Chronic inotropic therapy was initiated in 1 patient from each of the collateral and no collateral groups (2.9% and 4.2%; P=not significant).
Univariate analysis demonstrated that coronary collaterals, statin therapy, men, and higher pulse pressure were associated with improved outcomes in patients with CAV. In contrast, worse NYHA class, higher LVEDP, lower ejection fraction, higher heart rate, rejection, prednisone, and azathioprine therapy were associated with worse outcomes in patients with CAV (Table 2) . Among the variables examined, NYHA class and the presence of coronary collaterals represented the 2 most robust predictors of outcomes.
Cox multivariable models revealed that the presence of coronary collaterals was independently associated with improved outcomes in patients with CAV. We used 2 separate analyses to test whether coronary collateral development was an independent predictor of the primary end points. Within our cohort, 35 events contributed to the composite end point and 30 events contributed to all cause mortality. On the basis of prior studies demonstrating that multivariable models are most accurate when they include 10 events per variable, [28] [29] [30] we first constructed a multivariable model that included the 3 variables that most robustly predicted outcomes. This analysis demonstrated that angiographically visible collaterals were associated with all cause mortality (hazard ratio, 0.20; 95% confidence intervals, 0.08-0.54; P=0.001) and the composite end point (hazard ratio, 0.29; 95% confidence intervals, 0.11-0.74; P=0.010) independent of NYHA class and prednisone therapy (Table 3) . To confirm these findings, we developed a series of multivariable models which tested whether the presence of collaterals was independently associated with outcomes after adjusting for each individual variable. This analysis revealed that the presence of coronary collaterals was associated with a lower incidence of all cause mortality and the composite end point independent of NYHA class, ejection fraction, LVEDP, heart rate, pulse pressure, rejection, men, statin, azathioprine, and prednisone therapy (Table 3) .
Reduced Heart Failure Symptoms in Patients With Coronary Collaterals
To determine whether the presence of coronary collateral blood vessels impacts on heart failure symptoms in patients with CAV, we tested for an association between NYHA class, as documented in the clinical record at the time of CAV diagnosis, and the development of coronary collaterals. Consistent with improved outcomes in CAV patients with collaterals, the presence of coronary collaterals was associated with reduced NYHA class (P<0.001; Figure 3A ). The majority of CAV patients with coronary collaterals had either NYHA class I or II symptoms (29% and 56%, respectively). A small minority of patients with collaterals reported NYHA class III or IV symptoms (12% and 3%, respectively). In contrast, CAV patients without collaterals had significantly fewer patients with NYHA class I or II symptoms (4% and 27%, respectively). The majority of CAV patients without collaterals had NYHA class III or IV symptoms (58% and 11%, respectively). Trend analysis confirmed that the development of coronary collaterals in patients with CAV was associated with reduced NYHA class severity ( Figure 3B ).
Late Diagnosis Is Associated With Coronary Collateral Development
As mentioned previously, patients with CAV who form coronary collateral vasculature tended to be diagnosed later than Figure 4A ). Of note, patients in this study underwent coronary angiography on the basis of a strategy driven by a combination of routine screening, high-risk stress testing, or in the context of progressive heart failure symptoms. Thus, collateral formation may protect patients from the development of symptoms and lead to a later timing of diagnosis. Alternatively, an earlier diagnosis of CAV may indicate more aggressive disease. In this setting, there may not be adequate time to form collateral vasculature. To determine whether collateral formation was predictive of outcomes independent of the timing of diagnosis, we performed 2 additional analyses. Kaplan-Meier analysis using the time of CAV diagnosis as time zero demonstrated that patients with collaterals have a reduced incidence of all cause mortality and the composite end point compared with those without collaterals ( Figure 4B ). Furthermore, Cox multivariable models demonstrated that coronary collateral development and the time to diagnosis were independently associated with improved outcomes, supporting the notion that coronary ACEi/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blockers; BP, blood pressure; CI, confidence intervals; CMV, cytomegalovirus; EF, ejection fraction; ESRD, end stage renal disease; HR, hazard ratio; ICM, ischemic cardiomyopathy; LVEDP, left ventricular end-diastolic pressure; NYHA, New York Heart Association; and PCI, percutaneous coronary intervention. Figure 3 . Reduced heart failure symptoms in patients with coronary collaterals. A, Heart failure symptoms as defined by New York Heart Association (NYHA) class. Patients without coronary collaterals (black bars) had predominately NYHA class III symptoms while patients with coronary collaterals (gray bars) had predominately NYHA class II symptoms. B, Trend analysis demonstrating a statistically significant relationship between collateral formation and NYHA class. collaterals are protective and may delay the diagnosis of CAV ( Figure 4C ). The hazard for time to diagnosis was found to change over time (nonproportional) and was corrected for by adding the interaction to the model. This analysis led to the observation that the association between time to diagnosis and outcome weakened over time.
B
Microvascular Density
To gain further insight into why CAV patients with coronary collaterals have improved outcomes compared with those without collaterals, we obtained right ventricle (RV) endomyocardial biopsy specimens from patients included in this study. Selected biopsy specimens were collected within 1 to 2 months from the time that CAV was diagnosed and demonstrated minimal acute cellular rejection (grade O or 1A rejection). Adequate endomyocardial specimens were available from 22 of 25 (88%) patients in the no collateral group and from 31 of 34 (91%) patients in the collateral group. We also included 23 control samples that were matched based on the timing of transplantation. Demographic and outcome data comparing control and CAV patients are provided in Table I in the online-only Data Supplement. Control patients tended to be older than those with CAV and had a lower incidence of diabetes mellitus, a well-known risk factor for CAV. The groups were otherwise well balanced with respect to demographic data. As expected, patients with CAV tended to have a higher incidence of prior percutaneous coronary intervention and heart failure as demonstrated by decreased systolic BP, higher heart rate, higher LVEDP, worse NYHA class, and systolic dysfunction.
To examine alterations in microvascular density, we performed immunohistochemical staining with antibodies that specifically recognize endothelial cells and smooth muscle cell actin. Immunostaining for CD34 revealed that compared with controls, patients with CAV had significantly reduced microvasculature ( Figure 5A-5C and 5G) . The largest difference in microvascular density occurred between control subjects and CAV patients without collaterals where there was a >2-fold difference between groups (7.1±1.1% versus 3.2±0.9%; P<0.001). Although CAV patients with collaterals had reduced microvascular density compared with control subjects (5.2±1.4% versus 7.1±1.1%; P<0.001), these patients had significantly increased microvascular density compared with CAV patients without collaterals (5.2±1.4% versus 3.2±0.9%; P=0.001). Together, these data reveal that microvascular density is significantly reduced in patients with CAV and suggest that there is a significant association between collateral development and preservation of microvascular density. SMA immunostaining demonstrated that compared with controls, patients with CAV had significantly reduced arteriolar density ( Figure 5D -5F and 5H). Arteriolar density was quantified by counting the number of SMA+blood vessels per ×20 field. CAV patients without collaterals had a statistically significant reduction in arteriolar density compared with control subjects (5.8±1.4 versus 7.8±1.4 SMA+vessels per ×20 field; P<0.001). In contrast, there was no statistical difference in arteriolar density between CAV patients with collaterals and control subjects (7.0±1.9 versus 7.8±1.4 SMA+vessels per ×20 field; P=0.10).
Myocardial Fibrosis
Myocardial fibrosis is predictive of poor outcomes in patients who have been subjected to various cardiac insults. 31, 32 To characterize changes in myocardial fibrosis, we performed picrosirius red staining and quantified the percentage area stained. Compared with control subjects, patients with CAV demonstrated evidence of increased interstitial fibrosis ( Figure 6A-6D) . CAV patients without collaterals displayed significantly increased levels of fibrosis (9.7±3.0%) compared with both controls (2.9±1.6%; P<0.001) and CAV patients with coronary collaterals (5.5±2.7%; P<0.001). Patients with CAV and collaterals had reduced interstitial fibrosis compared with those without collaterals (P<0.01).
Consistent with increased interstitial fibrosis in CAV patients, patients with CAV had higher LVEDP compared with control subjects ( Figure 6E ). For these analyses, LVEDP was measured at the time of CAV diagnosis. CAV patients without collaterals (27.3±6.9 mm Hg) and CAV patients with collaterals (18.6±6.3 mm Hg) demonstrated increased LVEDP compared with control subjects (12.7±3.6 mm Hg; P<0.001). In addition, CAV patients without collaterals had significant higher LVEDP compared with CAV patients with collaterals (P<0.001). Linear regression analysis revealed that myocardial fibrosis and microvascular density were significant contributors to LVEDP (Figure 6F and 6G) . Myocardial fibrosis was positively correlated with LVEDP (r 2 =0.48; P<0.001), and microvascular density was inversely correlated with LVEDP (r 2 =0.49; P<0.001).
Discussion
The major finding of this study is that the development of collateral coronary vasculature predicts improved survival and allograft function in patients with moderate or severe CAV. The presence of coronary collaterals correlated with less severe heart failure symptoms as assessed by NYHA classification. Furthermore, coronary collaterals were associated with preserved microvascular density, reduced myocardial fibrosis, and decreased LVEDP.
The prognostic importance of collateral blood vessel development in CAD and ischemic cardiomyopathy has been well established. Patients who form angiographically visible collateral vasculature have reduced rates of cardiac mortality and major adverse cardiac events, compared with patients without collaterals. In addition, analyses of physiological assessment of collateral perfusion as measured by collateral flow index have revealed improved outcomes in patients with increased collateral flow. [22] [23] [24] [25] [26] To date, there have been conflicting reports describing whether patients with CAV can develop collateral vasculature. In an angiographic study of 81 CAV patients, Gao et al 33 reported that in the setting of total vessel occlusion only 8% of patients had angiographically visible coronary collaterals. In contrast to these findings, Bajaj et al 34 described a series of 73 patients with CAV and demonstrated the presence of angiographically visible collaterals in the majority of subjects. In comparison to patients with native CAD, CAV patients had smaller collateral vessels that were described as having a myocardial blush pattern. Physiological evaluation using coronary artery occlusion pressure suggested that patients with CAV have identical collateral flow to those with native CAD. 35 Similarly, a recent study using propensity matching showed that patients with CAV have a collateral flow index that approximates those with native CAD. 36 Consistent with the latter observations, we found that the 34 of 59 (57%) patients with CAV had angiographically visible collaterals. The majority of patients had smaller sized collaterals that formed a web-like pattern ( Figure 1C ) consistent with prior reports. 34 Our analysis not only confirmed these prior findings, but also revealed that the formation of coronary collaterals portends a favorable prognosis in patients with CAV. We further demonstrated that collateral formation served as a powerful independent predictor of survival and cardiovascular outcomes in this patient population.
Importance of the Microvasculature
CAV has been demonstrated to affect the entire length of the coronary blood vessel from the epicardial artery to smaller intramyocardial arterioles. Abnormalities of the epicardial vasculature are readily identifiable by coronary angiography and intravascular ultrasound. Decreased microvascular perfusion has been demonstrated in patients with CAV using thrombolysis in myocardial infarction (TIMI) myocardial perfusion grade, coronary flow reserve, and positron emission tomography imaging. These studies also show an inverse correlation between epicardial plaque progression and microvasculature dysfunction, suggesting diffuse involvement of the coronary vascular tree. 37, 38 The importance of microvascular perfusion is supported by the correlation between survival and TIMI myocardial perfusion grade. 39 In support of the diffuse nature of CAV, analyses of endomyocardial biopsy specimens have revealed histological evidence of intramyocardial arteriole inflammation and endothelial cell injury. 38, 40 We further extend these observations to demonstrate that patients with CAV have significant reductions in microvascular density at the arteriole and capillary level.
Intriguingly, patients with angiographically visible collaterals demonstrated expansion of both the small arteriole and the capillary compartments, as compared with patients without collaterals. These data raise the possibility that a subgroup of patients with CAV are capable of activating a proangiogenic program resulting in simultaneous development of coronary collateral blood vessels, as well as preservation of microvascular density. This broad proangiogenic response is associated with improved outcomes, lessened severe heart failure symptoms, reduced myocardial fibrosis, and decreased LVEDP. The mechanistic explanation for which only a portion of patients undergo an expansion of their coronary vasculature in response to CAV is unknown and will be a focus of future studies.
Study Limitations
The primary limitation of this study is the sample size (n=59) and retrospective study design. We chose to only include patients with moderate-to-severe CAV. This was done to enrich for a patient population that definitively had CAV with a relatively high rate of adverse cardiovascular events at the expense of a smaller sample size. As a result, this approach may overestimate the mortality rate and exaggerate differences in event rates between patients with and without collaterals. Despite the small sample size, we were fortunate to capture a well-balanced group of patients with similar demographics and comorbidities and much of our data were consistent with previous reports. Pravastatin and simvastatin reduce disease progression and mortality in clinical trials, 11, 12 and azathioprine, as compared with mycophenolate, has previously been associated with an increased incidence of CAV. 15, 41 The relationship between prednisone therapy and outcomes in patients in CAV has not yet been reported and may be explained by direct effects of this agent, such as reduced angiogenesis and poor wound healing. 42 Alternatively, ongoing use of prednisone may serve as a surrogate marker of chronic rejection and more aggressive transplant vasculopathy.
The use of coronary angiography to identify patients with coronary collaterals and CAV represents a potential limitation of this study. Angiographic identification of collateral blood vessels is a less robust method compared with invasive measurements of plaque volume and collateral perfusion. 23 Intravascular ultrasound and coronary flow measurements were not available for the majority of patients in this study.
Another limitation of this study involves the use of RV endomyocardial biopsy specimens. Our findings are subjected to potential sampling error. That is, we are making the assumption that results obtained from RV endomyocardial biopsy specimens are reflective of changes throughout the heart, including the LV. In contrast, to native ischemic heart disease, the impact of potential sampling error may be minimized as CAV tends to globally affect the myocardium. 
Implications for Prognosis and Treatment
In terms of prognostic data, disease progression, as assessed by intravascular ultrasound, seems to provide the most definitive information and is associated with the development of allograft failure and mortality. 43, 44 Additionally, smaller clinical studies revealed that measurement of myocardial perfusion by either positron emission tomography or TIMI myocardial perfusion grade is associated with both plaque volume and clinical outcomes. 38, 39 These studies implicate the rate of plaque growth and absolute myocardial perfusion as central components of disease progression, each contributing to overall prognosis.
In this study, we add to the available prognostic data for the CAV patient population and show that coronary collateralization as assessed by angiography is associated with significantly improved outcomes, including heart failure symptoms and mortality. The presence of coronary collateral vasculature was the single strongest prognostic predictor of survival in our cohort and was independently associated with clinical outcomes. We further demonstrated that patients who form coronary collateral blood vessels are more likely to have preserved microvascular density.
Together, the above data suggest that the intrinsic ability to grow new coronary vasculature on the large and small vessel level is central to outcomes in patients with CAV. Whether this is reflected by the previous findings of improved prognosis in patients with increased myocardial perfusion remains to be rigorously studied. It is intriguing to speculate that quantification of myocardial perfusion as assayed by modalities, such as cardiac positron emission tomography and MRI, may help to better predict outcomes in patients with CAV. Such an approach has the potential to identify patients who may benefit from retransplantation from those who would do well with medical therapy.
These findings have additional implications with respect to novel therapies for patients with CAV. Therapeutic angiogenesis has been proposed as a biological approach for revascularization in patients with ischemic cardiomyopathy and peripheral vascular disease. This strategy involves administration of growth factors or gene therapy to promote angiogenesis and collateral growth. Despite initial promise in phase I and II studies, larger clinical trials using growth factors, such as fibroblast growth factors (FGF2 and FGF4), vascular endothelial growth factors (VEGF-A and VEGF-B), and colony-stimulating growth factors (G-CSF and GM-CSF), have largely been disappointing. 45, 46 Whether these proangiogenic factors encompassed the most ideal targets remains a topic of much debate.
It is intriguing to consider the possibility that elucidation of the molecular mechanism by which coronary collaterals grow and mature in patients with CAV may provide critical insights into how these blood vessels form in patients with ischemic heart disease. The identification of molecules that are sufficient to promote coronary collateral growth may lead to the development of novel therapies for both of these diseases. It is conceivable that proangiogenic therapy may promote the development of collateral blood vessels in patients who are not able to form collateral vasculature and enhance collateral growth and maturation in those who have intrinsic collaterals. 
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